Kirtane, Kedar http://orcid.org/0000-0003-1302-9577
Geiss, Carley
Arredondo, Brandy
Hoogland, Aasha I.
Chung, Christine H.
Muzaffar, Jameel
Patel, Krupal B.
Gonzalez, Brian D.
Jim, Heather S. L.
Oswald, Laura B.
Article History
Received: 20 September 2021
Accepted: 18 December 2021
First Online: 29 January 2022
Declarations
:
: The current research was approved by the Institutional Review Board at Advarra (Pro00045231).
: All participants provided verbal consent prior to study enrollment.
: Participants provided verbal consent to have de-identified data published.
: Christine Chung—honoraria from Sanofi and Exelexis for ad hoc Scientific Advisory Board participation. Brian Gonzalez—paid consultant for SureMed Compliance and KemPharm outside this work and advisor for Elly Health outside this work. Heather Jim—paid consultant for RedBill BioPharma, Janssen Scientific Affairs, and Merck outside this work. Kedar Kirtane—owns stock in Veru, Oncternal Therapeutics, and Seattle Genetics. The authors have no other relevant conflicts of interest to disclose.
Free to read: This content has been made available to all.